🇺🇸 FDA
Company

Design

Design Therapeutics

DSGN pharma USA

Quick answer

Design is a pharma company (DSGN) headquartered in CARLSBAD, CA, USA with 24 tracked pipeline programs.

Pipeline (24)

project

Abiraterone - Usual

Prostate Cancer

Phase 3 · small_molecule · active

1 trials project

Alectinib - Usual

ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Phase 3 · small_molecule · active

1 trials project

Amchafibrin

Osteoarthritis, Knee

Phase 3 · small_molecule · completed

1 trials project

Cloxacilin

Staphylococcus

Phase 3 · small_molecule · terminated

1 trials project

Conventional medical treatment

Coronary Atherosclerosis and Other Heart Disease

Phase 3 · small_molecule · completed

1 trials project

Discontinuation antipsychotic treatment

Psychosis Nos/Other

Phase 3 · small_molecule · active

1 trials project

ETOPOSIDE - Usual

Small Cell Lung Cancer

Phase 3 · small_molecule · active

1 trials project

Farxiga® (dapagliflozin) + Onglyza® (saxagliptin) + Metformin Oral Mix Treat type 2 diabetes

Type 2 Diabetes

Phase 3 · small_molecule · active

1 trials project

Influenza vaccine

Infection in Solid Organ Transplant Recipients

Phase 3 · mab · completed

1 trials project

LV305

Synovial Sarcoma

Phase 3 · mab · terminated

1 trials project

Levodopa

Ischaemic Stroke

Phase 3 · small_molecule · completed

1 trials project

Paclitaxel-releasing PTA balloon catheter

Arteriovenous Fistula Renal Dialysis Devices Obstruction

Phase 3 · other · completed

1 trials project

Platelet rich plasma

Coxarthrosis

Phase 3 · small_molecule · completed

1 trials project

REX-001

Peripheral Arterial Disease (PAD)

Phase 3 · small_molecule · terminated

2 trials project

Raloxifene - Usual

Breast Cancer

Phase 3 · small_molecule · active

1 trials project

Rituximab

Lupus Nephritis

Phase 3 · mab · terminated

1 trials project

Topotecan - usual

SCLC

Phase 3 · small_molecule · active

1 trials project

ALLOGENEIC AND EXPANDED ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS

Sars-CoV2

Phase 2 · small_molecule · completed

1 trials project

Adult Allogeneic Mesenchymal cells from adipose tissue.

Acute Graft Versus Host Disease

Phase 2 · small_molecule · completed

1 trials project

Anterior lamellar nanostructured artificial human cornea.

Severe Trophic Corneal Ulcers Refractory to Conventional Treatment

Phase 2 · small_molecule · completed

1 trials project

Autologous Bone Marrow Mononuclear Cells

Peripheral Vascular Diseases

Phase 2 · other · completed

1 trials project

Autologous adipose derived mesenchymal stem cells

Critical Limb Ischemia (CLI)

Phase 2 · small_molecule · completed

1 trials project

Autologous mesenchymal stem cells from adipose tissue.

Autoimmune Diseases

Phase 2 · other · completed

1 trials project

Bioengineered Artificial Mesenchimal Sheet (BAMS)

Venous Ulcer

Phase 2 · mab · active

1 trials

Patents (8)

patent

US 12378245

Crystalline forms of an RSK inhibitor

Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12297243

Methods and compositions for reducing the immunogenicity of chimeric notch recep

Expires Mon May 08 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12291058

Dispersions for additive manufacturing comprising discrete carbon nanotubes

Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12268695

Betulin-containing birch bark extracts and their formulation

Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12247004

2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their th

Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12065498

Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptor

Expires Mon Aug 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12005194

Configurable oxygen concentrator and related method

Expires Mon Jun 06 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11998571

Pharmaceutical composition comprising stem cell-conditioned medium and exosome i

Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)